What is ImmVirX?
ImmVirX is a pioneering immuno-oncology company that leverages proprietary bio-selected RNA viruses. These viruses are engineered to target specific receptor proteins that are highly expressed on various cancer cell types. By selectively entering, replicating within, and ultimately destroying tumor cells, ImmVirX's technology aims to not only eliminate cancerous growths but also to foster beneficial changes within the tumor micro-environment. This dual-action approach positions ImmVirX at the forefront of innovative cancer therapies.
How much funding has ImmVirX raised?
ImmVirX has raised a total of $47M across 2 funding rounds:
Other Financing Round
$22M
Series B
$25M
Other Financing Round (2021): $22M with participation from University of Newcastle Australia and Hunter Medical Research Institute
Series B (2023): $25M led by OneVentures and Acorn Capital Investment Fund
Key Investors in ImmVirX
OneVentures
OneVentures is a venture capital firm that invests in high-growth technology and life science companies. They focus on providing strategic capital and operational support to help their portfolio companies scale and achieve market leadership.
Acorn Capital Investment Fund
Acorn Capital Investment Fund is an investment manager specializing in emerging and microcap companies, particularly within Australia. They focus on identifying innovative businesses with strong growth potential and providing them with the necessary capital for expansion.
University of Newcastle Australia
The University of Newcastle, Australia, is an academic institution that supports research and innovation. Its involvement in funding suggests a focus on translating academic discoveries into commercial applications, particularly in scientific and medical fields.
What's next for ImmVirX?
The recent major strategic investment signals a pivotal growth phase for ImmVirX. This capital infusion is expected to accelerate the development and potential commercialization of its unique immuno-oncology platform. The company is likely to focus on expanding its research and development capabilities, potentially initiating or advancing clinical trials, and strengthening its strategic partnerships. ImmVirX's trajectory suggests a move towards scaling its operations and solidifying its market position in the competitive landscape of cancer therapeutics.
See full ImmVirX company page
